Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
iling Date		2006-09-18
irst Named Inventor	Taka	gaki et al
Art Unit		
Examiner Name		
Attorney Docket Numb	er	NANP136US

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	Releva		Lines where ges or Relev		
	1										
If you wis	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication de ⁴ Date Name of Patente Applicant of cited Document		e or	where Rel	or Relevant	70
	1	2005-047832	JP			2005-02-24					Ø
	2	2001-511153	JP			2001-08-07					Z
	3	11-302142	JP			1999-11-02	Sunstar Inc				V

Application Number Filing Date 2006-09-18 Filing Date 2006-09-18 Filing Date 2006-09-18 Filing Date Application Number Filing Date 2006-09-18 Filing Date 2006-09-18 Filing Date 2006-09-18 Filing Date Application Number 2006-09-18 Filing Date 2006-09-18

If you wisl	h to a	dd add	itional F	oreign P	atent De	ocume	ent cital	tion in	nforma	tion ple	ase	click the A	dd butto	n [Add			
					NO	N-PAT	TENT L	ITER	RATUR	E DOC	UM	ENTS		E	Remov	е		
Examiner Initials*	Cite No	(book	k, magaa		nal, ser	ial, syr	mposiu	m, ca				rticle (whe pages(s),						Тs
	1	Interr	national S	Search Re	port for I	PCT/JP	2005/0	04035	5 dated	May 10	, 200	05						
	2	YANAGIDA et al, Inhibitory Effects of Apple Polyphenols and Related Compounds on Carogenic Factors of Mutans Streptococci, J. Agrie. Food Chem, 2000, Vol. 48, No. 11, PP. 5665-5671, Japan																
If you wis	h to a	dd add	fitional n	on-paten	t literati	ure do	cumen	t citat	tion in	ormatic	on pl	ease click	the Add	butt	on A	١dd		
							EXAM	NER	SIGN	ATURE								
Examiner	Signa	ture									П	Date Cons	sidered	Г				
												nce with M					ugh a	

See Kind Codes of USPTO Plantin Documents at twee USPTO, QCV or MPPP 991.04. * Enter office and assess the document, by the to-electrood (WIPO Standard ST3.). **Explainase plants documents, the reduction or the paser of the region or the Engerer must proceed the senial number of the patent document. **Indicated Cocument by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here it from the patent document of the patent docu

Application Number Filing Date 2006-09-18 Fil

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first clied in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Greg Turocy/	Date (YYYY-MM-DD)	2006-09-18
Name/Print	Gregory Turocy	Registration Number	36952

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.